Gamma Frequency Has An Efficient Effect On Alzheimer's Disease

Contact Tina  tina.xiang@wecistanche.com for more info.

In the early 20th century, German neuropathologist Alois Alzheimer first identified a case of progressive dementia, which was later named Alzheimer's disease (AD).

According to public information, "Alzheimer's disease is a neurodegenerative disease with a slow onset and progressive deterioration over time." Its etiology is still unknown, and it has become one of the major problems in the medical field.

Previously, Cognito Therapeutics unveiled its first digital therapy product for Alzheimer's disease. The product, a non-invasive neurostimulation device using Gamma frequency technology, has been certified by the U.S. Food and Drug Administration (FDA) as a "breakthrough device" for the digital treatment of Alzheimer's disease.

Cognito Therapeutics is a U.S.-based clinical-stage company developing digital therapeutics for neurodegenerative diseases such as Alzheimer's.

It is reported that the company's proprietary neuromodulation platform technology was developed by professors Li-Huei Tsai and Edward Boyden in the Department of Brain and Cognitive Sciences at MIT. It is a non-invasive therapy for neurodegenerative diseases that treats patients with visual and auditory sensory stimulation.

Recently, at the 2021 2021 AD/PD Conference, Cognito Therapeutics announced Phase 2 data results for its latest Gamma frequency neuromodulation therapy.

Gamma frequency neuromodulation is a novel digital therapy method that uses electroencephalogram (EEG)-calibrated auditory and visual stimuli to evoke neural activity in patients.

Zach Malchano, President of Cognito Therapeutics, said: "Gamma frequency neuromodulation is beneficial in Alzheimer's disease compared to traditional pharmacological approaches, which may be facilitated by a differentiated pathway. We are pleased Can advance the clinical development of gamma frequency neuromodulation therapy, either as a stand-alone therapy or in combination with other treatments being developed for Alzheimer's disease."

Phase 2 study of gamma-frequency neuromodulation therapy lasting 6 months, using a multicenter randomized controlled trial (RCT) to evaluate the therapy during the treatment period in people with mild to moderate Alzheimer's disease safety and effectiveness.

The study shows that gamma frequency neuromodulation therapy is not only safe and effective but also well tolerated.

It is understood that the study recruited 76 patients 50 years and older with mild to moderate Alzheimer's disease, and let them randomly receive 40Hz non-invasive audiovisual or sham stimulation for one hour during daily treatment.

During the 6-month treatment period, the investigators used multiple validated measures to periodically assess changes in subjects' cognition, function, and biomarkers.

In addition, the study assessed changes in brain volume in Alzheimer's patients with mild to moderate cognitive impairment.

The findings showed that Alzheimer's patients treated with gamma frequency neuromodulation experienced dramatic improvements in memory, cognition, brain atrophy, and volume loss.

It is understood that compared with patients in the placebo group, patients in the treatment group in the study had a significant reduction in Alzheimer's disease-related whole-brain atrophy and volume loss by 61%.

Placebo refers to a drug that does not have any therapeutic effect by itself. In clinical medicine research, in order to observe the efficacy of a certain drug, it is used in the control group to stabilize the patient's mood.

Also, after 6 months of gamma frequency neuromodulation, the treatment group experienced an 84% slower decline in Activities of Daily Living (ADCS-ADL) and a slower decline in Mini-Mental State Examination (MMSE) within 6 months 83%.

"We look forward to accelerating the clinical development of gamma frequency neuromodulation, which promises to be the first disease-modifying digital therapy for Alzheimer's disease," said Brent Vaughan, CEO of Cognito Therapeutics.

Recently, at the 2021 Alzheimer's Association International Conference (AAIC 2021), Cognito Therapeutics once again presented the latest clinical research data on gamma frequency neuromodulation.

Brain atrophy in patients with Alzheimer's disease is closely related to cognitive decline and functional loss and is an important factor in the morbidity and mortality of Alzheimer's disease.

Studies have shown that gamma frequency neuromodulation can significantly reduce brain atrophy in people with Alzheimer's disease. During the 6-month treatment period, patients in the treatment group experienced a 65% reduction in total brain volume loss compared to the control group.

In addition, abnormal sleep is associated with the development and progression of Alzheimer's disease, and improving sleep is an important approach in the treatment of Alzheimer's disease. Studies have shown that people with mild to moderate Alzheimer's disease have reduced active periods during nighttime sleep when treated with gamma frequency neuromodulation.

"Neurophysiological medical approaches can influence disease progression by improving memory, cognitive and functional symptoms, and reducing brain atrophy, and the improved nighttime sleep in Alzheimer's patients demonstrated this time provides a new perspective for us," Vaughn said. Altering the mechanism of the disease in the patient population provides further support. This is an important milestone and we look forward to expanding the clinical validation of Cognito Therapeutics in pivotal Alzheimer's studies."